Reference
NICE. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Internet Document : 24 May 2017. Available from: URL: https://www.nice.org.uk/guidance/ta445/chapter/1-Recommendations
Rights and permissions
About this article
Cite this article
NICE recommends certolizumab and secukinumab for PsA. PharmacoEcon Outcomes News 779, 36 (2017). https://doi.org/10.1007/s40274-017-4051-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4051-3